US Patent Issued to Regeneron Pharmaceuticals on May 19 for "Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments" (New York Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,890, issued on May 19, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments" was invented by Alina Baum (Pleasantville, N.Y.), Benjamin Fulton (New York), Christos Kyratsous (Irvington, N.Y.) and George D. Yancopoulos (Yorktown Heights, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections)."

The patent was ...